Recent Updates
06
ANAPTYSBIO ANNOUNCES NEW STRATEGIC ANTIBODY DISCOVERY ALLIANCES WITH TWO PHARMA PARTNERS
January 6th, 2012
SAN DIEGO, Calif. – AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company. The strategic alliance announced today with Novartis is AnaptysBio’s second collaboration with the Swiss-based pharmaceutical company and follows an initial partnership where AnaptysBio successfully delivered antibody candidates for Novartis’ development pipeline. (more…)
23
A Sweet Deal: How Amira Reinvented Itself as a Drug Discovery Engine
December 23rd, 2011
Xconomy
By: Bruce V. Bigelow
The sale of Amira Pharmaceuticals will likely go down as one of the standout life sciences deals of 2011—it certainly ranks as one of the biggest payouts in San Diego, where Amira was founded in 2005. (more…)
24
Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
October 24th, 2011
PRNewswire
Syndax Pharmaceuticals, Inc., a late-stage epigenetics oncology company, announced today that members of management will present at the following upcoming fall conferences: (more…)
11
AnaptysBio Appoints Carol G. Gallagher as Executive Chair and Promotes Senior Leaders Hamza Suria and David J. King
October 11th, 2011
BusinessWire
Team will advance SHM-XELTM antibody platform to build therapeutic pipeline
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Carol G. Gallagher has joined its board of directors as Executive Chair. In addition, AnaptysBio has promoted Hamza Suria to chief business officer and acting chief executive officer, and David J. King to chief scientific officer. (more…)
29
Otonomy Presents Positive New Findings from Phase 1b Study of OTO-104 in Ménière’s Disease at International Conference
September 29th, 2011
| Observed Clinical Activity Suggests OTO-104 Provides Clinically Meaningful Reduction in Vertigo Frequency and Improvement in Tinnitus
San Diego, CA, September 29, 2011 — Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company’s lead product candidate, OTO-104, in patients with Ménière’s disease. The presented data showed that patients treated with OTO-104 experienced clinically meaningful reductions in vertigo frequency and improvements in tinnitus as compared to placebo. These results were presented today in an oral presentation at the 28th Politzer Society Meeting in Athens, Greece. (more…) |